This Viewpoint argues against the early use of docetaxel chemotherapy in the treatment of prostate cancer.
This Viewpoint argues for early use of chemotherapy in patients diagnosed with prostate cancer.
This Viewpoint describes the rising cost of Death With Dignity Act prescriptions which makes assisted death a less-viable option for patients with fewer than 6 months to live.
This Viewpoint evaluates The Death of Cancer and the role of oncologists as friends or relatives of patients with cancer.
This meta-analysis examines the prognostic value of minimal residual disease assessment as associated with survival outcomes in patients with newly diagnosed multiple myeloma.
This cohort study uses data from the Breast Cancer Surveillance Consortium to evaluate the 10-year cumulative risk of breast cancer in women with atypical ductal hyperplasia that was diagnosed on needle biopsy vs excisional biopsy.
This reanalysis of the EORTC “boost vs no boost” trial examines the long-term impact of prognostic factors on ipsilateral breast tumor recurrence in patients treated with breast-conserving therapy.
This cohort study uses clinical informatics to examine the association of androgen deprivation therapy for prostate cancer with the development of dementia.
This phase 2 randomized clinical trial examines the effect of arginine deprivation plus best supportive care vs best supportive care alone in patients with argininosuccinate synthetase 1–deficient malignant pleural mesothelioma.
This study uses data from a clinical trial comparing docetaxel vs mitoxantrone for metastatic castration-resistant prostate cancer to investigate the association between the number of docetaxel cycles and overall survival in patients who benefitted from docetaxel.
This study uses the US National Cancer Database to compare overall survival following primary cytoreductive surgery vs neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer.
This cohort study assesses whether improved locoregional control is associated with a survival benefit in patients with early-stage extranodal natural killer/T-cell lymphoma in China.
This study describes the effectiveness of a combined intervention that included oncologist communication training and coaching for patients with advanced cancer and caregivers in improving patient-centered communication.
This population-based study, using the SEER and Medicare databases, looks at the association between regional practices in use of radiotherapy for ductal in situ breast cancer with later use of mastectomy.
This review examines the mechanisms of viral carcinogenesis, with an emphasis on the viral evasion of the host immune system, and discusses how to harness the immune system as a therapeutic tool in select malignant cancers.
This commentary compares the results of the ALaCaRT study with 3 large randomized clinical trials comparing laporoscopic vs open surgery for rectal cancer resection.
This commentary reviews the results of the ACOSOG Z6051 randomized clinical trial, which compared outcomes of laparoscopic resection vs open resection in patients with rectal cancer.
A woman in her 70s with stage 3A squamous cell carcinoma of the lung was enrolled in a clinical trial in which she received combination therapy with pembrolizumab and an investigational agent; 3 months into treatment, she developed multiple thick, mildly pruritic, yellow, hyperkeratotic plaques on her lower extremities. What is your diagnosis?
This Clinical Evidence Synopsis summarizes a Cochrane review that analyzes the association between lymphadenectomy and survival, disease recurrence, and surgical morbidity in women with presumed early-stage, low-grade endometrial carcinoma.
This cohort study assesses whether fingerprint loss is an unexpectedly frequent adverse effect of treatment with capecitabine.
This cohort study examines a hospital-based national cancer registry to assess whether chemoradiotherapy plus proctectomy vs chemoradiotherapy without surgery is associated with worse overall survival in patients with nonmetastatic rectal adenocarcinoma.